Importance The optimal maintenance strategy after induction chemotherapy with anti–
epidermal growth factor receptor antibody for patients withRASwild-type metastatic …

Anti-EGFR targeting is one of the key strategies in the treatment of metastatic colorectal
cancer (mCRC). For almost two decades oncologists have struggled to implement EGFR …

Colorectal cancer (CRC) is the third most common cancer and the second leading cause of
cancer death worldwide. Clinical research results have provided more treatment …

Background Anti-EGFR antibodies plus doublet chemotherapy is the standard of care in
RAS/BRAF wild-type metastatic colorectal cancer (mCRC). No phase-3 level of evidence is …

According to current guidelines, doublet chemotherapy plus an anti–epidermal growth factor
receptor (EGFR) agent is the recommended upfront treatment option in patients with RAS or …

在全球范围内结直肠癌已经是最常见的癌症之一. 近些年来, 结直肠癌持续上升的发病率给社会
经济带来了巨大压力. 尽管治疗手段在不断地进步, 但是结直肠癌的死亡率仍居高不下 …

Introduction In metastatic RAS wild-type colorectal cancer (CRC), induction combination
chemotherapy doublets (CT) with an anti-EGFR agent are considered the primary treatment …

With more than 1.9 million new cases, colorectal cancer (CRC) accounted in 2020 for 10%
of all diagnosed cancers. CRC ranked third in terms of incidence and was the second …

Заместитель директора по научной работе НИИ клинической онкологии им. акад. РАН
и РАМН НН Трапезникова ФГБУ «НМИЦ онкологии им. НН Блохина» Минздрава …